Salarius Pharmaceuticals, Inc. (SLRX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 21, 2025

$2.48

P/E Ratio

N/A

Market Cap

$3.57M

Jan 25, 2024Feb 29, 2024Apr 3, 2024May 6, 2024Jun 10, 2024Jul 16, 2024Aug 19, 2024Sep 24, 2024Oct 29, 2024Dec 3, 2024Jan 21, 2025$10.00$20.00
  • SEMR
Description

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Metrics

Overview

  • HQHouston, TX
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSLRX
  • Price$2.48-7.81%

Trading Information

  • Market cap$3.57M
  • Float97.48%
  • Average Daily Volume (1m)7,048,862
  • Average Daily Volume (3m)2,151,236
  • EPS-$8.19

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$0.97M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$1.01M
  • EV-$1.11M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B1.22
Documents